Stock Killers World

[NWriter]

$RGC is up 20% this week!

$RGC is a company which took heavy hit last week due to possible short attacks by traders and hedge funds.
This week, investors who bought the dip at bargain of $28 dollars are up by 20% as their reward.

Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.

A little background on the CEO, its investors and stock-option plan which we know so far,

- Chairman and CEO support.

? Since RGC’s incorporation in October 2014 up to the IPO, the Company has been fully funded by its Chairman and CEO, Mr. Yat-Gai Au. (whom is also a practitioner of TCM)

?Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50.

? Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;

? Will not award share options for himself;

? Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased [49,010 shares](https://www.sec.gov/Archives/edgar/data/0001829667/000121390022026630/ea160018-13da4regen_regen.htm) (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million).

- Billionaire investor backing
Samuel Chen, a successful early Zoom Video Communications (NASDAQ:ZM) investor is one of the major backers of RGC. Last reported 13G filing shows he holds a 7.63% stake in the company.

- Stock option lock-up extended
All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.